Contrast-enhanced CBCT With C-arm HyperSight Technology

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity Health Network, Toronto

About this trial

This is a single-arm prospective, feasibility study evaluating the intravenous contrast-enhanced cone beam computed tomography (IV CBCT) for image guidance during radiotherapy. Patients treated with SFRT will receive IV-contrast enhanced CT and fMRI before treatment for simulation purposes. Additionally, patients will receive mpMRI just before and IV-contrast enhanced CBCT during their second and last fraction of RT, in addition to the standard of care CBCT that is acquired for daily image-guided patient positioning. Patients will undergo both IV-contrast enhanced CBCT and treatment on the TrueBeam with HyperSight imaging capability. We hypothesize IV contrast enhanced CBCT is feasible, well-tolerated by patients and improves the visibility of the target.

Eligibility criteria

Qualifiers

Primary biopsy-proven cancer

Planning to undergo spatially fractionated radiation therapy

Able to provide informed consent

Willingness to participate in follow-up

Disqualifiers

Unable to understand/provide consent

History of allergic reaction to iodinated IV contrast dye (allergy to MR contrast is not an exclusion criteria)

Known renal disease

Single kidney

Trial design

Treatments tested in this trial

  • Intravenous contrast-enhanced cone beam computed tomography

Treatment groups

20 Participants
are divided into 1 treatment group